Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2004 Mar-Apr;24(2B):943-54.

Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors.

Author information

1
Drug Discovery Program, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, Florida 33612, USA.

Abstract

BACKGROUND:

Cancer-related molecular targets of green tea polyphenols, such as (-)-epigallocatechin-3-gallate [(-)-EGCG], remain unknown. We previously showed that (-)-EGCG is a potent and specific inhibitor of the proteasomal chymotrypsin-like activity in vitro and in vivo.

MATERIALS AND METHODS:

EGCG amides and five simple analogs were prepared by enantioselective synthesis. Proteasome inhibition in vitro was measured by fluorogenic substrate assay and in vivo by accumulation of proteasome target proteins (p27, IkappaB-alpha and Bax). Inhibition of tumor cell proliferation was determined by G1 arrest, DNA fragmentation and colony formation inhibition.

RESULTS:

EGCG analogs with modifications in the A-ring, C-ring or ester bond inhibit the chymotrypsin-like activity of purified 20S proteasome with altered potencies. However, these compounds were able to potently inhibit the proteasome activity in vivo and also suppress colony formation of prostate cancer LNCaP cells. Some compounds caused G1 arrest and DNA fragmentation in leukemia Jurkat T cells. However, these EGCG analogs caused no or little proteasome inhibition in normal or nontransformed cells.

CONCLUSION:

The A-ring and gallate ester/amide bond are essential for the proteasome-inhibitory function of (-)-EGCG.

PMID:
15161048
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center